Head Of U.S.-based Inviragen Outlines Reasoning Behind Recent Merger With Singapore's SingVax
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The head of the U.S.-based Inviragen said the outfit opted to merge with Singapore's SingVax because the combined companies' vaccine development pipelines and international product development capabilities fit together so perfectly